Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06480565 | RECRUITING | Clear Cell Renal Cell Carcinoma

A Phase 1/2 Trial of ADI-270 in ccRCC
Sponsor:

Adicet Therapeutics

Brief Summary:

This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.

Condition or disease

Clear Cell Renal Cell Carcinoma

Intervention/treatment

ADI-270

Fludarabine

Cyclophosphamide

Phase

PHASE1

PHASE2

Study Type : INTERVENTIONAL
Estimated Enrollment : 60 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase 1/2 Trial of ADI-270 (Engineered γδ Chimeric Receptor [CAR] Vδ1 T Cells Targeting CD70) in Adults With Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC)
Actual Study Start Date : 2024-12-12
Estimated Primary Completion Date : 2025-06
Estimated Study Completion Date : 2027-06

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Histologically or cytologically confirmed clear cell RCC
  • 2. Documented evidence of advanced or metastatic diseases.
  • 3. Patients must have been treated with an immune checkpoint inhibitor and a VEGF inhibitor (the VEGF inhibitor must have been administered in the advanced and/or metastatic setting).
  • 4. At least one measurable target lesion according to RECIST 1.1
  • 5. At least three weeks, or 5 half-lives, whichever is shorter, from the last dose of the prior line of systemic therapy
  • 6. KPS ≥ 70
Exclusion Criteria
  • 1. Subjects with CNS metastases or spinal cord compression are not eligible, unless they have completed therapy and have discontinued the use of corticosteroids for at least 8 weeks and remained stable prior to enrollment.
  • 2. Clinically significant CNS dysfunction of any etiology in the opinion of the Investigator.
  • 3. Prior radiation therapy within 21 days prior to start of study treatment with the exception of palliative radiotherapy to bone lesions (palliative radiotherapy to bone lesions must be completed at least 2 weeks prior to the first dose of LD).
  • 4. Active malignancy (except for RCC, definitively treated basal or squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix or bladder) within the past 24 months
  • 5. Treatment with gene therapy, genetically modified cell therapy, or adoptive T cell therapy within 6 weeks before initiating LD in this study.
  • 6. Receipt of CD70 targeted therapies for any indication
  • 7. Require corticosteroid therapy \> 5 mg per day of prednisone or equivalent.
  • 8. History of any form of primary immunodeficiency such as severe combined immunodeficiency disease.
  • 9. Presence of active autoimmune disease requiring ongoing systemic immunosuppressive therapy.
A Phase 1/2 Trial of ADI-270 in ccRCC

Location Details

NCT06480565

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, California

Adicet Clinical Trials

Redwood City, California, United States, 94065